Induction and Maintenance Infliximab Therapy for the Treatment of Moderate-to-Severe Crohn’s Disease in ChildrenJeffrey S. Hyams, Robert N. Baldassano, Wallace Crandall et al.|Gastroenterology|2006Cited by 872
Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort studySubra Kugathasan, Marla C. Dubinsky, Lee A. Denson et al.|The Lancet|2017Cited by 647
Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signatureYael Haberman, Lee A. Denson, Timothy L. Tickle et al.|Journal of Clinical Investigation|2014Cited by 532
Induction and Maintenance Therapy With Infliximab for Children With Moderate to Severe Ulcerative ColitisJeffrey S. Hyams, Anne M. Griffiths, Lakshmi Damaraju et al.|Clinical Gastroenterology and Hepatology|2011Cited by 282
Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel DiseaseJeffrey S. Hyams, Meena Thayu, Marla C. Dubinsky et al.|Gastroenterology|2017Cited by 217